Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, in
- This topic has 0 replies, 1 voice, and was last updated 10 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Phase (Ph) 1/2 study of TSR-011, a potent inhibitor of ALK and TRK, including crizotinib-resistant ALK mutations.
http://abstracts.asco.org/144/AbstView_144_134653.html
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.